Tempest Therapeutics, Inc. Net Income (Loss) Attributable to Noncontrolling Interest
Tempest Therapeutics, Inc. (TPST) reported Net Income (Loss) Attributable to Noncontrolling Interest of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-11.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2020-03-11
- Tempest Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2018-12-31 was $691.00K.
- Tempest Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2018-09-30 was -$355.00K.
- Tempest Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2018-06-30 was -$196.00K.
- Tempest Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2018-03-31 was -$125.00K.
- Tempest Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- Tempest Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2018 was $15.00K.
- Tempest Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2017 was -$8.00K.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-11 | |||
| 2018-12-31 | $691.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $336.00K derived: sum of 2 quarters · filed 2020-03-11 | $140.00K derived: sum of 3 quarters · filed 2020-03-11 | $15.00K 10-K · filed 2020-03-11 |
| 2018-09-30 | -$355.00K 10-Q · filed 2019-11-13 | -$551.00K derived: sum of 2 quarters · filed 2019-11-13 | -$676.00K 10-Q · filed 2019-11-13 | |
| 2018-06-30 | -$196.00K 10-Q · filed 2019-08-12 | -$321.00K 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | -$125.00K 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | -$8.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |